One of the earliest hallmark preclinical studies of first generation menin inhibitors, MI-463 and MI-503, demonstrated high potency inhibition of menin in KMT2A-rearranged leukemia cell lines and a substantial survival benefit in mice models harboring KMT2A-rearranged leukemia [48]. Here, MEN1 is linked to leukemia.